RPL8

Across TCGA pan-cancer cohorts, RPL8 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RPL8 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPL8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL8 expression acts as an unfavorable survival marker, although some lineages such as COAD and HNSC show a favorable association.

CCRCC, LSCC, and COAD are the cancer types where RPL8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.528	0.848	.006	23	view →
LSCC	DFS	Median	III,IV	0.328	0.938	<.001	21	view →
COAD	DFS	Median	III,IV	1.000	0.897	.044	12	view →
HNSC	DFS	Median	All	0.986	0.921	.013	10	view →
LUAD	DFS	Quartile	All	0.973	0.561	.002	10	view →
PDAC	DFS	Median	II,III,IV	0.819	0.690	.010	8	view →
GBM	DFS	Median	All	0.277	0.453	.008	5	view →
UCEC	DFS	Median	All	0.963	0.848	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RPL8–CCRCC (OS)

Open the CCRCC breakdown →